N-Terminally Truncated and Pyroglutamate-Modified Aβ Forms Are Measurable in Human Cerebrospinal Fluid and Are Potential Markers of Disease Progression in Alzheimer’s Disease

N-Terminally Truncated and Pyroglutamate-Modified Aβ Forms Are Measurable in Human Cerebrospinal Fluid and Are Potential Markers of Disease Progression in Alzheimer’s Disease

Alzheimer’s disease (AD) is a pathology characterized by the accumulation in the brain of intracellular and extracellular amyloid-β (Aβ) aggregates, especially of Aβ1–40 and Aβ1–42 peptides. It is known that N-terminally truncated or modified Aβ forms also exist in AD brains and cerebrospinal fluid...

Full description

Bibliographic Details
Main Authors: Guido Domingo, Luisa Benussi, Claudia Saraceno, Michela Bertuzzi, Roland Nicsanu, Antonio Longobardi, Sonia Bellini, Alfredo Cagnotto, Mario Salmona, Giuliano Binetti, Roberta Ghidoni
Format: Article
Language:English
Published: Frontiers Media S.A. 2021-07-01
Series:Frontiers in Neuroscience
Subjects:
Alzheimer’s disease
mass spectrometry
beta - amyloid peptide
cerebrospinal fluid
pyroglutamate-modified amyloid beta-peptide
Online Access:https://www.frontiersin.org/articles/10.3389/fnins.2021.708119/full

Internet

https://www.frontiersin.org/articles/10.3389/fnins.2021.708119/full

Similar Items